Desvenlafaxine
Product Images NDC 50090-4388

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-4388). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Image 1)

Chemical structure diagram of Desvenlafaxine dihydrogen succinate monohydrate showing the molecular arrangement of its active ingredient.*

FDA Label Image

1 (Image 2)

A forest plot chart titled 'Impact of Intrinsic Factors on Desvenlafaxine Pharmacokinetics,' showing geometric mean ratios with 90% confidence intervals for different pharmacokinetic measures (Cmax, AUC) across categories of renal impairment, hepatic impairment, and population descriptions (gender, age). The x-axis represents change relative to reference, ranging from 0.5 to 3.5.*

FDA Label Image

2 (Image 3)

A horizontal bar graph showing the geometric mean ratio (90% CI) for pharmacokinetic changes in Desvenlafaxine due to CYP3A4 inhibitor ketoconazole. The graph includes two variables, Cmax and AUC, with their respective ratios relative to reference values and confidence intervals displayed.*

FDA Label Image

3 (Image 4)

A chart illustrating the geometric mean ratio with 90% confidence intervals for the pharmacokinetic effects of desvenlafaxine on various interacting drugs at different dosages. The chart lists changes in Cmax and AUC for desipramine, midazolam, tamoxifen, and aripiprazole substrates at specified desvenlafaxine ER tablet strengths, showing the impact on drug concentration and exposure relative to reference values.*

FDA Label Image

4 (Image 5)

A line graph comparing the estimated proportion of patients with relapse over time between Desvenlafaxine 50 mg and placebo. The x-axis represents time to relapse in days from randomization, and the y-axis shows the estimated proportion of patients with relapse in percentage. Two lines illustrate relapse trends for Desvenlafaxine 50 mg and placebo groups.*

FDA Label Image

5 (Image 6)

A line graph comparing the estimated proportion of patients with relapse (%) over time in days from randomization between Desvenlafaxine and placebo groups. The x-axis represents time to relapse (days), ranging from 0 to 180, and the y-axis shows the proportion of patients relapsing, ranging from 0% to 50%. Desvenlafaxine is represented by a solid line with a lower relapse rate compared to placebo shown by a dashed line.*

FDA Label Image

Label Image (Lbl500904388)

Desvenlafaxine 25 mg extended-release tablets by A-S Medication Solutions. The label includes NDC 50090-4388-0, product number 6892-0, and storage instructions to keep between 68 to 77 degrees Fahrenheit. The package contains 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.